News | November 2, 2021

Biozek Medical Test For Covid-19 Antigen Has MHRA Registration In The United Kingdom

In an ongoing effort to help bolster the United Kingdom's fight against COVID-19, Biozek Medical, the Netherlands based biotechnology company, has announced MHRA registration of their COVID-19 Antigen Rapid test.

The Biozek COVID-19 Antigen Rapid test requires a simplistic nasal or throat swab, delivering rapid results in 15-minutes. The innovative diagnostic test offers a high accuracy of 98.98%, providing an added layer of protection and reassurance as the UK deals with the ever-changing global pandemic.

The test is easy to use by healthcare professionals or self-administered, with no additional laboratory equipment necessary. The simple visual representation offers an intelligible diagnosis of infection or non-infection. Compared to other PCR and rapid tests on the market, the Biozek COVID-19 Antigen Rapid test is more affordable, offering UK individuals and organizations a high standard of quality — at a fraction of the cost.

Zeki Hamid, CEO at Biozek Medical, states, "Despite easing of lockdown restrictions in the UK, the COVID-19 pandemic remains an ongoing health crisis, with new variants working diligently to undo our global community efforts. We believe continuous rapid testing, alongside vaccination efforts, is the best strategy as we transition into the next phase of the new normal".

Since MHRA registration, Biozek Medical has developed and released a COVID-19 Antigen Rapid test that utilizes a less-invasive saliva sampling method.

With the highly transmittable mutation known as the Delta variant spreading countrywide, Biozek Medical believes its new saliva rapid test is a critical tool against all known and mutating variants.

Source: Biozek